{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:11:12Z","timestamp":1784131872534,"version":"3.55.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Streptococcus pneumoniae causes invasive pneumococcal disease and pneumonia. This study models the burden of adult pneumococcal disease in France. Over a 5-year period, approximately 630 000 cases and \u20ac3.1 billion of costs were attributable to pneumococcus, mostly noninvasive disease, with nearly 80% due to serotypes included in 20-valent pneumococcal conjugate vaccine.<\/jats:p>","DOI":"10.1093\/ofid\/ofag381","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:57:46Z","timestamp":1782921466000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in the 20-Valent Pneumococcal Conjugate Vaccine in the Adult Population in France"],"prefix":"10.1093","volume":"13","author":[{"given":"Euan","family":"Dawson","sequence":"first","affiliation":[{"name":"HTA, Value & Evidence, Pfizer Inc. , Tadworth ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8013-2399","authenticated-orcid":false,"given":"St\u00e9phane","family":"Fi\u00e9vez","sequence":"additional","affiliation":[{"name":"Access & Value, Pfizer , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Blanc","sequence":"additional","affiliation":[{"name":"Medical & Scientific Affairs, Pfizer , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5610-3098","authenticated-orcid":false,"given":"Jeffrey","family":"Vietri","sequence":"additional","affiliation":[{"name":"HTA, Value & Evidence, Pfizer Inc. , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rozenbaum","sequence":"additional","affiliation":[{"name":"HTA, Value & Evidence, Pfizer Inc. , Capelle a\/d Ijssel ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5235-0868","authenticated-orcid":false,"given":"Liem Binh Luong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Cochin Port-Royal, DMU PROMIIS, CIC Cochin Pasteur, Universit\u00e9 de Paris Cit\u00e9, Inserm , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"2026071511511506800_ofag381-B1","doi-asserted-by":"crossref","first-page":"ofae349","DOI":"10.1093\/ofid\/ofae349","article-title":"Hospital burden of all-cause pneumonia and nonbacteremic pneumococcal pneumonia in adults in France between 2013 and 2019","volume":"11","author":"Sabra","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026071511511506800_ofag381-B2","volume-title":"Bilan annuel 2023: incidence des infections invasives \u00e0 pneumocoque et impact de la vaccination","author":"Sante Publique","year":"2025"},{"key":"2026071511511506800_ofag381-B3","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00937-20","article-title":"A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus","volume":"11","author":"Ganaie","year":"2020","journal-title":"mBio"},{"key":"2026071511511506800_ofag381-B4","doi-asserted-by":"crossref","first-page":"104937","DOI":"10.1016\/j.idnow.2024.104937","article-title":"The latest news in France before distribution of third-generation pneumococcal conjugate vaccines","volume":"54","author":"Cohen","year":"2024","journal-title":"Infect Dis Now"},{"key":"2026071511511506800_ofag381-B5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14760584.2020.1750378","article-title":"Upper respiratory tract colonization with Streptococcus pneumoniae in adults","volume":"19","author":"Arguedas","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"2026071511511506800_ofag381-B6","volume-title":"Strat\u00e9gie de vaccination contre les infections \u00e0 pneumocoque - place du vaccin pneumococcique polyosidique conjugu\u00e9 (20-valent, adsorb\u00e9) chez l\u2019adulte","author":"Haute Autorit\u00e9 de Sant\u00e9 (HAS)","year":"2023"},{"key":"2026071511511506800_ofag381-B7","doi-asserted-by":"crossref","first-page":"e0329703","DOI":"10.1371\/journal.pone.0329703","article-title":"Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: a retrospective population-based study in France","volume":"20","author":"Wyplosz","year":"2025","journal-title":"PLoS One"},{"key":"2026071511511506800_ofag381-B8","volume-title":"\u00c9largissement des crit\u00e8res d'\u00e9ligibilit\u00e9 \u00e0 la vaccination antipneumococcique chez les adultes - recommandation vaccinale","author":"Haute Autorit\u00e9 de Sant\u00e9 (HAS)","year":"2025"},{"key":"2026071511511506800_ofag381-B9","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/pathogens12050732","article-title":"Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults","volume":"12","author":"Farrar","year":"2023","journal-title":"Pathogens"},{"key":"2026071511511506800_ofag381-B10","doi-asserted-by":"publisher","first-page":"S1473-3099(26)00115-5","DOI":"10.1016\/S1473-3099(26)00115-5","article-title":"Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort study","author":"Miles","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"2026071511511506800_ofag381-B11","volume-title":"Strat\u00e9gie de vaccination contre les infections invasives \u00e0 pneumocoques: place du vaccin CAPVAXIVE chez l\u2019adulte","author":"Haute Autorit\u00e9 de Sant\u00e9 (HAS)","year":"2025"},{"key":"2026071511511506800_ofag381-B12","volume-title":"Infections \u00e0 pneumocoque : recommandations vaccinales pour les adultes","author":"Haute Autorit\u00e9 de Sant\u00e9 (HAS)","year":"2017"},{"key":"2026071511511506800_ofag381-B13","volume-title":"Population par \u00e2ge en 2024 - France - TABLEAU DE BORD DE L\u2019\u00c9CONOMIE FRAN\u00c7AISE","author":"Institut national de la statistique et des \u00e9tudes \u00e9conomiques (Insee)","year":"2024"},{"key":"2026071511511506800_ofag381-B14","volume-title":"Rapport annuel D'Activite 2025 - CNR pneumocoques","author":"Varon","year":"2025"},{"key":"2026071511511506800_ofag381-B15","volume-title":"CAP'HOSPI - serotype distribution in hospitalized adult with pneumococcal community acquired pneumonia in France","author":"Luong","year":"2025"},{"key":"2026071511511506800_ofag381-B16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13696998.2025.2458957","article-title":"Assessing the economic impact and healthcare resource utilization of inpatient pneumococcal disease among adults: a French national claims database study","volume":"28","author":"Bailey","year":"2025","journal-title":"J Med Econ"},{"key":"2026071511511506800_ofag381-B17","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.vaccine.2016.03.013","article-title":"CAPECO: cost evaluation of community acquired pneumonia managed in primary care","volume":"34","author":"Personne","year":"2016","journal-title":"Vaccine"},{"key":"2026071511511506800_ofag381-B18","author":"INED (Institut National d'\u00e9tudes D\u00e9mographiques)"},{"key":"2026071511511506800_ofag381-B19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.idnow.2021.07.006","article-title":"Adults at risk of pneumococcal disease in France","volume":"51","author":"Wyplosz","year":"2021","journal-title":"Infect Dis Now"},{"key":"2026071511511506800_ofag381-B20","doi-asserted-by":"crossref","first-page":"ofz510","DOI":"10.1093\/ofid\/ofz510","article-title":"Factors associated with severe nonmeningitis invasive pneumococcal disease in adults in France","volume":"6","author":"Danis","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026071511511506800_ofag381-B21","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.3390\/microorganisms11112781","article-title":"Pneumococcal serotypes associated with community-acquired pneumonia hospitalizations in adults in Spain, 2016-2020: the CAPA study","volume":"11","author":"Men\u00e9ndez","year":"2023","journal-title":"Microorganisms"},{"key":"2026071511511506800_ofag381-B22","volume-title":"R\u00e9partition des s\u00e9rotypes de vaccins pneumococciques dans les pneumonies aigu\u00ebs communautaires n\u00e9cessitant une hospitalisation chez l'adulte en France, in 25th journees nationales d'Infectiologie","author":"Luong","year":"2024"},{"key":"2026071511511506800_ofag381-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41533-024-00405-7","article-title":"Description and characterization of pneumococcal community acquired pneumonia (CAP) among radiologically confirmed CAP in outpatients","volume":"35","author":"Le Bel","year":"2025","journal-title":"NPJ Prim Care Respir Med"},{"key":"2026071511511506800_ofag381-B24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3345\/kjp.2012.55.11.424","article-title":"Enhanced detection and serotyping of Streptococcus pneumoniae using multiplex polymerase chain reaction","volume":"55","author":"Ahn","year":"2012","journal-title":"Korean J Pediatr"},{"key":"2026071511511506800_ofag381-B25","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1093\/cid\/cir048","article-title":"Interpreting assays for the detection of Streptococcus pneumoniae","volume":"52 Suppl 4","author":"Blaschke","year":"2011","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag381\/68695704\/ofag381.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag381\/68695704\/ofag381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag381\/68695704\/ofag381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:51:27Z","timestamp":1784130687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag381\/8724723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag381","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"ofag381"}}